We are pleased to announce the positive results of our Usher syndrome and retinitis pigmentosa clinical study Stellar, which has met all its stated objectives. This marks a crucial milestone in our ongoing inherited retinal disease research.
Even in lockdown we have been working hard as ProQRians to stay connected to the inherited retinal disease community. Rare Disease Day is a unique awareness day due to its global reach and significance.
We caught up with Lance Johnson, a podcaster and video editor, living with autosomal dominant retinitis pigmentosa (adRP). Since moving to New York City, Lance has started the See-Through Podcast, championing people from across the disability community.
We are pleased to announce the completed enrollment of Illuminate, our Phase 2/3 pivotal clinical trial of in Leber congenital amaurosis 10, or LCA10. Marking an important milestone in our ongoing inherited retinal disease research.
Podcast about genetic testing for inherited retinal disease and how getting a genetic diagnosis empowers the IRD community. The guests are Kari Branham (genetic counsellor) and Ben Shaberman (Foundation Fighting Blindness).
Using a new digital format, the EFF welcomed over 50 stakeholders to discuss continued clinical development in Leber congenital amaurosis 10 (LCA10) and the importance of both the expert clinical and patient perspectives in research.
The ProQR family is growing fast and we spoke to the Chief Medical Officer Aniz Girach who joined ProQR in 2019. We asked him about his impression of the company after he joined, as well as the new developments he’s been working on.
He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.